GlaxoSmithKline PLC (GSK.L)

GSK.L on London Stock Exchange

1,303.50GBp
12:10pm EDT
Change (% chg)

-35.00p (-2.62%)
Prev Close
1,338.50p
Open
1,327.00p
Day's High
1,327.50p
Day's Low
1,300.50p
Volume
6,866,592
Avg. Vol
9,313,876
52-wk High
1,645.00p
52-wk Low
1,247.50p

GSK.L

Chart for GSK.L

About

GlaxoSmithKline plc. (GSK) is a healthcare company that researches and develops pharmaceuticals, vaccines and consumer healthcare products. The Company operates in two segments: Pharmaceuticals and Vaccines, and Consumer Healthcare. The Pharmaceuticals segment develops and makes medicines to treat a range of acute and chronic... (more)

Overall

Beta: 0.64
Market Cap(Mil.): £65,139.91
Shares Outstanding(Mil.): 4,866.63
Dividend: 19.00
Yield (%): 5.98

Financials

  GSK.L Industry Sector
P/E (TTM): 6.67 35.80 35.95
EPS (TTM): 2.01 -- --
ROI: 30.62 15.54 14.99
ROE: 149.51 16.12 15.87
Search Stocks

EU mergers and takeovers (Aug 21)

BRUSSELS, Aug 19 - The following are mergers under review by the European Commission and a brief guide to the EU merger process:

21 Aug 2015

EU Commission clears Perrigo to buy GSK units

BRUSSELS, Aug 21 - The European Commission cleared on Friday U.S. drugmaker Perrigo's acquisition of certain assets from Britain's GSK.

21 Aug 2015

Novartis buys remaining rights to GSK treatment for up to $1 billion

ZURICH - Novartis has agreed to buy all remaining rights to Ofatumumab from Britain's GlaxoSmithKline for up to $1 billion, boosting the Swiss drugmaker's stable of multiple sclerosis (MS) treatments.

21 Aug 2015

UPDATE 1-Novartis buys remaining rights to GSK treatment for up to $1 bln

* Will pay royalties of up to 12 pct on future net sales (Adds comment from head of Novartis Pharmaceuticals, detail)

21 Aug 2015

Novartis buys remaining rights to GSK treatment in deal up to $1 bln

ZURICH, Aug 21 - Swiss drugmaker Novartis said on Friday it had agreed to buy all remaining rights to Ofatumumab, which is being developed for relapsing remitting multiple sclerosis and other autoimmune indications, from Britain's GlaxoSmithKline.

21 Aug 2015

BRIEF-GSK to divest ofatumumab auto-immune rights to Novartis for up to $1 bln

* GSK to divest ofatumumab for auto-immune indications to Novartis for up to $1 billion plus royalties

21 Aug 2015

EU mergers and takeovers (Aug 18)

BRUSSELS, Aug 18 - The following are mergers under review by the European Commission and a brief guide to the EU merger process:

18 Aug 2015

GSK hopes big clinical trial can breath new life into lung drug

LONDON, Aug 13 - GlaxoSmithKline is banking on a major clinical trial to revive its flagging respiratory medicine business, with billions of dollars of sales riding on a positive result.

13 Aug 2015

UPDATE 1-GSK shuts U.S. plant due to bacteria, no supply disruption seen

Aug 12 - Drugmaker GlaxoSmithKline temporarily closed a North Carolina factory on Tuesday after testing at a cooling tower found bacteria that causes deadly Legionnaire's disease.

12 Aug 2015

GSK closes North Carolina plant after Legionnaires' bacteria found

- Drugmaker GlaxoSmithKline closed its North Carolina factory on Tuesday after testing at a cooling tower found bacteria that causes deadly Legionnaire's disease, a company spokeswoman said.

11 Aug 2015

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : Stock Traders Daily
$20.00
Provider : Jefferson Research
$20.00
Provider : ValuEngine, Inc.
$25.00
Provider : S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks